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Introduction {#sec1}
============

The COVID-19 outbreak caused by SARS-CoV-2 infection ([@bib27], [@bib38], [@bib51], [@bib52]) has been declared as a global pandemic. Typical clinical symptoms of COVID-19 are fever, cough, myalgia, and shortness of breath ([@bib20], [@bib47]). Severe cases often develope acute lung injury, or the fatal form, acute respiratory distress syndrome (ARDS) ([@bib7], [@bib20], [@bib47]). To date, no specific antiviral treatment is available for COVID-19.

The infection of certain respiratory viruses has often resulted in a robust inflammatory response ([@bib11], [@bib18]). This immune dysregulation, termed hypercytokinemia or "cytokine storm," is often associated with detrimental outcomes such as ARDS ([@bib11]). To date, it remains elusive how pathogen infections disrupt the host immune homeostasis and stimulate a hyperactive proinflammatory response. A proposed model has suggested that viral evasion of the innate immune response plays a critical role ([@bib10]): the virus can effectively blind the immune system, causing an inadequate or delayed response. This immune escape gives rise to the unrestrained virus replication, which eventually results in a hyperactivated proinflammatory response.

Type I IFN (IFN-I) response plays a critical role in combating virus infection, mainly by inducing the expression of interferon-stimulated genes (ISGs) that exert antiviral functions ([@bib40]). Meanwhile, viruses have developed strategies to counteract IFNs. For example, SARS-CoV can efficiently suppress IFN induction and antagonize IFN's effect by harnessing its structural and non-structural proteins ([@bib12]). SARS-CoV infection failed to induce competent IFN response in cultured cells ([@bib8], [@bib44], [@bib53]) and SARS patients ([@bib37]). The inadequate IFN response may account for the progressive increase of viral load in SARS patients, the concomitant hypercytokinemia, and the ultimate fatal outcomes.

Clinical study on COVID-19 has suggested the hypercytokinemia in severe cases ([@bib20]). However, a more comprehensive investigation of the host immune response is needed. Here, we collected the bronchoalveolar lavage fluid (BALF) of eight COVID-19 patients, 146 community-acquired pneumonia patients, and 20 healthy controls; this is followed by metatranscriptome sequencing and functional analysis. The molecular signatures of the host response, especially the innate immune response to SARS-CoV-2 infection, are explicitly depicted, showing distinct patterns from those seen in SARS and pneumonia caused by other pathogens.

Results {#sec2}
=======

Sample Collection, Metatranscriptome Sequencing, Differential Expression Gene Analysis {#sec2.1}
--------------------------------------------------------------------------------------

BALFs were obtained from laboratory-confirmed COVID-19 patients (SARS2) (n = 8), community-acquired pneumonia patients (CAP) (n = 146), and healthy controls without known respiratory diseases (Healthy) (n = 20). The demographic and clinical characteristics of the cohorts are detailed in [Table S1](#mmc2){ref-type="supplementary-material"}. By metatranscriptome sequencing, more than 20 million reads were generated for each BALF sample from SARS2, CAP, and Healthy. Among them, 56% of the reads could be mapped to the human genome and were used for further analysis. As metatranscriptome data enabled us to capture the transcriptionally active microbes, we further classified CAP into two categories: Virus-like CAP (determined by at least 100 viral reads and 10-fold higher reads than those in the negative controls) and Non-viral CAP. The read counts for SARS-CoV-2 in each COVID-19 case were listed in [Table S2](#mmc1){ref-type="supplementary-material"}.

Differentially expressed genes (DEGs) were then identified by comparing pneumonia transcriptomes with the healthy control transcriptomes (SARS2 versus Healthy \[SARS2-H\], Virus-like CAP versus Healthy \[Vir-H\], and Non-viral CAP versus Healthy \[NonVir-H\]). An adjusted p value (q-value \< 0.05) and fold change (FC) ratio (\|log2FC\| ≥ 2) were used to determine the DEGs ([Tables S3](#mmc1){ref-type="supplementary-material"}A--S3C). The volcano plot showed that the number of DEGs in SARS2-H was markedly higher than that in Vir-H and NonVir-H, suggesting that SARS-CoV-2 infection strongly perturbed transcriptome homeostasis of cells in the lung ([Figure 1](#fig1){ref-type="fig"} A). The principal component analysis revealed that SARS2 formed distinct clusters, while Virus-like CAP and Non-viral CAP clusters were more widely dispersed and overlapped ([Figure 1](#fig1){ref-type="fig"}B), showing the disparate characteristics of DEGs in SARS2 from others.Figure 1Analysis of DEGs in BALF of COVID-19 and CAP Patients Compared to Healthy Controls(A) Volcano plot of DEGs comparing SARS2 versus Healthy (SARS2-H), Virus-like CAP versus Healthy (Vir-H), and Non-viral CAP versus Healthy (NonVir-H). The names of DEGs with the top 20 absolute FC are shown.(B) PCA loading plot based on all DEGs. Autoscaling of data was performed.(C) Functional enrichment analysis of DEGs with IPA. Asterisks (^∗^) indicate q-values \< 0.05 and absolute *Z* score ≥ 1.(D) PPI network of upregulated DEGs in SARS2 comparing to Healthy. Each node represents a protein, and interactions with confidence score \> 0.9 are presented.See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

We next collated genes whose expression is mostly regulated (\|log2FC\| ≥ 5) in SARS2-H ([Figure S1](#mmc1){ref-type="supplementary-material"}A). Expression levels of proinflammatory cytokine and chemokine genes (*IL-1B*, *CXCL17*, *CXCL8*, and *CCL2*), typical antiviral ISGs (*IFIT* and *IFITM* family genes), and calgranulin genes that exert pleiotropic functions in inflammatory disorders (*S100A8*, S100A9, and *S100A12*) were upregulated in SARS2 as compared to Healthy ([Figure S1](#mmc1){ref-type="supplementary-material"}A). Meanwhile, we observed marked upregulation of *IL1RN* and *SOCS3* ([Figure S1](#mmc1){ref-type="supplementary-material"}A), both of which encode cytokine signaling antagonists, suggesting that the negative feedback loops were elicited. Genes involved in morphogenesis and migration of immune cells (*NCKAP1L*, *DOCK2*, *SPN*, and *DOCK10*) were underexpressed ([Figure S1](#mmc1){ref-type="supplementary-material"}A). A host of DEGs was also observed when comparing CAPs to Healthy, albeit with much lower fold changes ([Figure S1](#mmc1){ref-type="supplementary-material"}A).

Global Functional Analyses {#sec2.2}
--------------------------

We then performed global functional analyses. For pathway analysis, we applied the Ingenuity Pathway Analysis (IPA) and KEGG analyses on DEGs. In IPA, "Interferon Signaling" ranked first in the upregulated pathways in SARS2 (Z score = 3.3, [Figure 1](#fig1){ref-type="fig"}C). This pathway is also upregulated, though to a lesser extent, in Virus-like CAP (Z score = 1), whereas not in the Non-viral CAP ([Figure 1](#fig1){ref-type="fig"}C), indicating robust IFN response in SARS-CoV-2 infection. The pathways involved in the inflammatory response in SARS2 was revealed by both analyses, with upregulated "Role of IL-17F in Allergic Inflammatory Airway Diseases" (Z score = 3.0) and "Chemokine Signaling" (Z score = 1.6) in IPA ([Figure 1](#fig1){ref-type="fig"}C), along with "Chemokine signaling pathway," "IL-17 signaling pathway," "TNF signaling pathway," and "NF-κB signaling pathway" in KEGG (q \< 0.05, [Figure S1](#mmc1){ref-type="supplementary-material"}B). Moreover, both IPA and KEGG analyses showed that DEGs from SARS2-H were strongly and specifically enriched in mRNA translation-related categories, with upregulated "EIF2 Signaling" (Z score = 3.3, [Figure 1](#fig1){ref-type="fig"}C) in IPA and "Ribosome" (q \< 0.05, [Figure S1](#mmc1){ref-type="supplementary-material"}B) in KEGG. Intriguingly, several neuron function-related pathways were specifically downregulated in SARS2 by IPA analysis, including "CREB Signaling in Neurons" (*Z* score = −1.1), "Synaptogenesis Signaling Pathway" (*Z* score = −1.4), and "Endocannabinoid Neuronal Synapse Pathway" (*Z* score = −2.1, [Figure 1](#fig1){ref-type="fig"}C). This unexpected observation awaits further investigation.

Next, we build protein-protein interaction (PPI) networks with the upregulated DEGs in SARS2 by STRING ([Figures 1](#fig1){ref-type="fig"}D and [S2](#mmc1){ref-type="supplementary-material"}). A dominant network comprising several subnetworks was generated using the confidence score of 0.9. Genes in the top two enriched KEGG categories ([Figure S1](#mmc1){ref-type="supplementary-material"}B)--- namely, "Ribosome" and "Chemokine signaling pathway"---formed two most densely connected subnetworks, which are mainly composed of ribosomal proteins and chemokines, respectively ([Figure 1](#fig1){ref-type="fig"}D). Overall, our global functional analysis revealed a highly responsive state against noxious stimuli in COVID-19 cases, characterized by the potent defense responses and hyperactive ribosome biogenesis.

Cytokine Profiles {#sec2.3}
-----------------

To understand the cytokine profile in BALF from the COVID-19 patients, we assigned DEGs into seven categories of cytokine-related genes ([Figure 2](#fig2){ref-type="fig"} A). In categories of "Chemokine" and "Receptor," multiple genes were more remarkably upregulated in SARS2 than those in CAPs. Several genes were regulated in the "Interleukin" and "Tumor necrosis factor" categories, and few were modulated in other categories ([Figure 2](#fig2){ref-type="fig"}A). To examine potential cytokine expression dynamics, we aligned individual cases according to the increasing days between sampling and symptom onset. Expression levels of cytokine-related genes seem to decrease over time, with one patient (C4) who eventually deceased being the outlier ([Figure 2](#fig2){ref-type="fig"}A). These observations suggested that the exuberant inflammation in COVID-19 could be progressively resolved, and unquenched inflammation may result in detrimental outcomes.Figure 2Cytokine-Related Gene Expressions in COVID-19 and CAP Patients(A) Heatmap of 218 genes encoding cytokines and receptors.(B) Heatmap of DEGs encoding cytokines and receptors. SARS2 samples (n = 8) were ordered by days after symptom onset (DSO) in the right panel of (A) and (B). Asterisks (^∗^) indicate significant DEGs (absolute log2FC ≥ 2, q-value \< 0.05). Relative viral reads (calculated by the ratio of SARS-CoV-2 reads to human reads) and the ratios of IL1B to IL1RN are shown in (A) and (B).

Chemokines are predominant among upregulated cytokine-related genes in SARS2 ([Figure 2](#fig2){ref-type="fig"}A). *CXCL17* ranked first in the upregulated chemokines. *CXCL17* upregulation is specific to SARS2 and was observed in all eight cases ([Figure 2](#fig2){ref-type="fig"}B), suggesting a role of *CXCL17* in COVID-19 pathogenesis. *CXCL8*, the archetypal neutrophil chemoattractant, together with *CXCL1* and *CXCL2*, was upregulated ([Figure 2](#fig2){ref-type="fig"}B). These chemokines are thought to be critical for recruiting neutrophils into the inflamed lung ([@bib14], [@bib15], [@bib31]). *CXCR2*, the receptor for *CXCL8*, *CXCL1*, and *CXCL2*, was also markedly upregulated ([Figure 2](#fig2){ref-type="fig"}B). Moreover, we observed the upregulation of *CCL2* and *CCL7*, both of which are vital for monocyte recruitment ([@bib43]) ([Figure 2](#fig2){ref-type="fig"}B). By presenting individual cases in the heatmap, one case (C1) with ultra-high viral reads ([Table S2](#mmc1){ref-type="supplementary-material"}) exhibited the most pronounced chemokine upregulation ([Figure 2](#fig2){ref-type="fig"}B), suggesting that higher virus replication resulted in a more robust proinflammatory response. Corroborating this, in three cases (C1, C2, and C5) sampled at the same time after symptom onset (day 8), the increases of viral load corresponded with the upregulations of critical chemokines, including *CXCL8*, *CCL2*, *CCL7*, etc. ([Figure 2](#fig2){ref-type="fig"}B). Both CAPs showed less DEGs and lower expression of cytokine genes as compared to SARS2 ([Figure 2](#fig2){ref-type="fig"}B).

*IL1RN* and *ILB* are interleukin genes significantly upregulated in SARS2 ([Figure 2](#fig2){ref-type="fig"}B), and these upregulations are mirrored by elevated protein levels of IL-1Ra and IL-1β in plasma of COVID-19 patients ([@bib20]). Because IL-1β was recognized as the key cytokine driving proinflammatory response in BALF from patients with ARDS ([@bib36]), it is possible that the ratio of IL-1β to its inhibitor, IL-1Ra, may correlate to inflammation intensity in COVID-19 patients; however, we did not observe clear correlation in the current study ([Figure 2](#fig2){ref-type="fig"}B).

Signatures of IFN Response {#sec2.4}
--------------------------

We then examined the IFN response in COVID-19 patients. By intersecting our data with a list composed of 628 ISGs ([@bib32]), we found that SARS2 showed more markedly elevated expression of ISGs than CAPs, and the expression seems decreased over time, again with the fatal case (C4) being the outlier ([Figure 3](#fig3){ref-type="fig"} A). Eighty-three ISGs were significantly elevated in SARS2, suggesting the robust IFN response ([Table S4](#mmc4){ref-type="supplementary-material"}). ISGs known to exert direct antiviral activity were upregulated, including *IFIT* and *IFITM* genes that exert broad-spectrum antiviral functions (*IFIT1*, -*2*, *-3,* and *IFITM1*, *-2*, *-3*) and others (*ISG15* and *RSAD2*) ([@bib13], [@bib17], [@bib35]) ([Figure 3](#fig3){ref-type="fig"}B). Among those, IFITMs have been shown to inhibit cellular entry of SARS-CoV and MERS-CoV ([@bib19], [@bib48]). Moreover, we observed the increased expression of *IFIH1, TANK, IRF7,* and *STAT1*, which may further potentiate IFN signaling ([Figure 3](#fig3){ref-type="fig"}B).Figure 3Expression of ISGs in COVID-19 and CAP Patients(A) Heatmap of 628 ISGs. SARS2 samples (n = 8) were ordered by days after symptom onset (DSO) in the right panel.(B) Heatmap of 83 upregulated ISGs in SARS2 comparing to Healthy. Asterisks (^∗^) indicate significant DEGs (absolute log2FC ≥ 2, q-value \< 0.05).(C) Upregulated ISGs in SARS-CoV-2 infection identified in this study, as well as in SARS-CoV and other viral infections (see [Table S4](#mmc4){ref-type="supplementary-material"}).In (B) and (C), ISGs were assigned into five biclusters.

In addition to antiviral activity, ISGs may exert diverse functions. We assigned these ISGs to five previously established functional clusters ([@bib32]), including RNA processing (C1 and C2), IFN regulation andantiviral function (C3), metabolic regulation (C4), and inflammation regulation (C5) ([Table S4](#mmc4){ref-type="supplementary-material"}). Surprisingly, ISGs are substantially enriched in the cluster of C5 (29 out of 83) ([Figure 3](#fig3){ref-type="fig"}B), which mainly comprises inflammation mediators or regulators. *CCL2* and *CXCL10*, two IFN-inducible chemokine genes found in C5 ([Figure 3](#fig3){ref-type="fig"}B), were also elevated in peripheral blood of patients with SARS ([@bib2]). These results pointed to the immunopathological role of IFN response in COVID-19 patients. Further, using a curated ISG list from patient blood transcriptomes ([@bib32]) and data from peripheral blood of SARS patients ([@bib2], [@bib37]), we compared the ISG distributions in the five clusters between SARS-CoV-2 and other viruses. ISGs identified in infections of yellow fever virus (live attenuated vaccine), HCV, EBV, and dengue virus were primarily assigned to C3 with less involvement of C5, while SARS-CoV-2 exhibited overly high C5 distribution ([Figure 3](#fig3){ref-type="fig"}C, [Table S4](#mmc1){ref-type="supplementary-material"}). Compared to other viruses, SARS-CoV infections induced significantly fewer ISGs ([Figure 3](#fig3){ref-type="fig"}C, [Table S4](#mmc1){ref-type="supplementary-material"}). Together, our results unveiled the unique signatures of IFN response in SARS-CoV-2 infection.

Cell Composition Analyses {#sec2.5}
-------------------------

The compositions of BALF cells could reflect immune cell profiles in the affected lung ([@bib9]). Using the transcriptome data, we estimated immune cell types and their proportions by CIBERSORT ([@bib34]). Similar to findings in BALF from healthy adults ([@bib30]), the BALF cell components in Healthy were mainly macrophages and lymphocytes ([Figure 4](#fig4){ref-type="fig"} A). This result supported the accuracy of the BALF cell sequencing and the effectiveness of our analytical approach. Among innate immune cells, activated dendritic cells, activated mast cells, and neutrophils were more abundant in viral pneumonia groups than those in Healthy ([Figure 4](#fig4){ref-type="fig"}B). SARS2 showed a more pronounced increase in neutrophils than other pneumonia ([Figure 4](#fig4){ref-type="fig"}B). Compared to innate immune cells, the composition of T cells and B cells was less varied among pneumonia groups and Healthy ([Figure S3](#mmc1){ref-type="supplementary-material"}A). A recent study suggested that the neutrophil-to-lymphocyte (NLR) ratio was associated with the disease severity of COVID-19 ([@bib26]). Our analysis also showed a significantly higher NLR in COVID-19 cases ([Figure S3](#mmc1){ref-type="supplementary-material"}A). The highest NLR was observed in the case with ultra-high viral reads and robust cytokine andISG expression ([Figures S3](#mmc1){ref-type="supplementary-material"}B and S3C).Figure 4Composition of Immune Cells in BALF Predicted from Transcriptome Data(A) The proportion of nine major immune cell types.(B) The proportion of 12 innate-immunity-related cell subtypes. Asterisks represent significant differences between groups (^∗^q-value \< 0.05, ^∗∗^q-value \< 0.01, ^∗∗∗^q-value \< 0.001, Mann-Whitney test).See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

Discussion {#sec3}
==========

Many of the transcriptomic profiling studies have been conducted by using intermittent samples such as peripheral blood ([@bib5]). However, some infections, such as avian influenza or SARS, occur in the lower respiratory tract ([@bib16], [@bib46]), where the immune response was triggered and regulated. Thus, blood transcriptome may not be optimal for profiling the immunopathological features in those scenarios. In the current study, we sampled COVID-19 patients with bronchoalveolar lavage (BAL), a method for retrieving cells and solutes from different areas of the lung ([@bib30]). By sequencing and analyzing the BAL fluid cells from eight COVID-19 patients and control cohorts, we obtained gene expression profiles of both host and virus, which directly reflected the *in situ* host response against SARS-CoV-2 infection. We thus provided a valuable opportunity to garner insights into COVID-19 pathogenesis.

In COVID-19 patients, we observed the upregulation of a plethora of proinflammatory cytokines, suggesting the pathogenic role of hypercytokinemia. The most salient feature of the cytokine profile is the chemokine response, as seen from the elevated expression of multiple chemokines and their receptors. Among those, various neutrophil chemoattractants were upregulated. Consonant with this, the higher neutrophil amount was observed in SARS2 by cell composition analysis. Also, chemoattractants for monocytes and other immune cells were significantly upregulated. In patients with ARDS, the alveolar spaces are occupied by the infiltrating neutrophils and monocytes ([@bib29]), suggesting the pathogenic role of those cells. Thus, our data unraveled a possible chemokine-dominant hyperactive cytokine response in COVID-19 cases.

In contrast to SARS-CoV, SARS-CoV-2 triggered a robust IFN response, hallmarked by the expression of numerous ISGs, including IFITMs shown to counteract SARS-CoV and MERS-CoV ([@bib19], [@bib48]). This protective potential of ISGs may account for the lower proportion of severe cases and the case-fatality rate in COVID-19 as compared to SARS ([@bib49]). Nevertheless, high SARS-CoV-2 loads were detected very early after symptom onset ([@bib54]), suggesting that the virus may have developed countermeasures against the IFN system such as delaying the IFN response by inhibiting innate immune signaling. Moreover, although robust ISG induction was observed, we failed to detect significant upregulation of IFNs. This discrepancy needs further investigation.

IFN-I could also be pathogenic. In the mouse model, depletion of IFN-α/β receptor protects mice from lethal infection of SARS-CoV ([@bib3]). Moreover, delayed IFN-β treatment failed to inhibit virus replication and aggravated pulmonary inflammation in the mice infected with MERS-CoV ([@bib4]). These data suggested that the timing of IFN therapy against SARS and MERS is critical. In the ISGs identified in COVID-19 cases, we found a subset of genes with proinflammatory activities, which is relatively underrepresented in other viral infections. These "proinflammatory ISGs" may assist the antiviral protection by amplifying inflammatory signals to the environment. However, they could also be deleterious in infections, especially when hypercytokinemia has already been triggered. As IFN treatment has been adopted as an antiviral therapy against SARS-CoV-2 infection (ChiCTR: ChiCTR2000029600), the timing and dose should be carefully considered.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Biological Samples**Human bronchoalveolar lavage fluid samplesPeking University People's Hospital, Shenzhen Third People's Hospital, Fujian Provincial Hospital, the Second Affiliated Hospital of Harbin Medical University, the First Affiliated Hospital of Xi'an Jiaotong University, and hospitals in WuhanNA**Chemicals, Peptides, and Recombinant Proteins**Trizol LSThermo Fisher ScientificCat\#10296028**Critical Commercial Assays**Direct-zol RNA Miniprep KitZymo ResearchCat\#R2051Trio RNA-Seq Library Preparation KitNuGENCat\#0357-32**Deposited Data**Reads mapped to human genome GRCh38 extracted from the raw sequencing dataThis paperGenome Warehouse in National Genomics Data Center <https://bigd.big.ac.cn/gsa>;\
Project number: PRJCA002273**Software and Algorithms**HISAT2 v2.1.0[@bib22]<http://ccb.jhu.edu/software/hisat2/>FeatureCounts 2.0.0[@bib25]<http://subread.sourceforge.net/>Fastp 0.20.0[@bib6]<https://github.com/OpenGene/fastp>Quantile normalization (Bioconductor limma package v3.42.2)[@bib39]<https://www.bioconductor.org/packages/release/bioc/html/limma.html>Ingenuity Pathway Analysis, December 2019 release (v499329)[@bib23]<https://digitalinsights.qiagen.com/>Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis (Bioconductor clusterProfiler package v3.14.3)[@bib50]<https://bioconductor.org/packages/release/bioc/html/clusterProfiler.html>STRING v11[@bib45]<https://string-db.org>Cytoscape v3.7.1[@bib41]<https://cytoscape.org>CIBERSORT algorithm v1.06[@bib34]<https://cibersort.stanford.edu/>Samtools 1.9[@bib24]<http://samtools.sourceforge.net/>

Resource Availability {#sec4.2}
---------------------

### Lead Contact {#sec4.2.1}

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Jianwei Wang (<wangjw28@163.com>).

### Materials Availability {#sec4.2.2}

This study did not generate new unique reagents.

### Data and Code Availability {#sec4.2.3}

The accession number for the reads mapped to human genome GRCh38 extracted from the raw sequencing data reported in this paper is \[Genome Warehouse in National Genomics Data Center ([@bib33])\]: \[PRJCA002273\] that is publicly accessible at <https://bigd.big.ac.cn/gsa>.

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

BALF samples from eight laboratory-confirmed COVID-19 patients (SARS2) were collected from hospitals in Wuhan in January 2020. BALFs from 146 community-acquired pneumonia patients (CAP) and 20 healthy controls from volunteers without any known pulmonary diseases (Healthy) were collected from Peking University People's Hospital, Shenzhen Third People's Hospital, Fujian Provincial Hospital, the Second Affiliated Hospital of Harbin Medical University, and the First Affiliated Hospital of Xi'an Jiaotong University between 2014 and 2018. CAP was diagnosed following guidelines of the Infectious Diseases Society of America and the American Thoracic Society ([@bib28]). The known respiratory pathogens in CAP patients were screened by using FTD Respiratory pathogens kit (Fast Track Diagnostics, Luxembourg). The study was approved by the Institutional Review Board of hospitals where sampling was carried out. The data collection for the COVID-19 patients were deemed by the National Health Commission of the People's Republic of China as the contents of the public health outbreak investigation. The written informed consent was obtained from all subjects before inclusion. Of the COVID-19 cases, five were male and three were female. Of the CAP cases, 75 were male and 54 were female. Eight COVID-19 cases had an average age of 49 years (range 40-61), and 112 CAP cases had an average of 56.4 years (range 22-91). The healthy subjects were pre-screened, and 20 had no known respiratory diseases were included as healthy control. Currently or potentially immunocompromised subjects with active cancer, primary immunodeficiency disorders, HIV infection, or tuberculosis infection were excluded from the study. Subjects with a recent medical record of taking immunosuppressive medications were excluded from the study. The detailed information of the subjects could be found in the demographic and clinical Table ([Table S1](#mmc2){ref-type="supplementary-material"}).

Method Details {#sec4.4}
--------------

### Sample Preparation and Sequencing {#sec4.4.1}

BALF samples were obtained during bronchoscopies done as part of clinical management. In the biosafety level (BSL)-III laboratory, a 200 ul aliquot of each BALF sample from COVID-19 patients were lysed in Trizol LS (Thermo Fisher Scientific, Carlsbad, CA, USA), followed by RNA extraction using a Direct-zol RNA Miniprep kit (Zymo Research, Irvine, CA, USA) according to the manufacturer's instructions. RNA extractions from other samples were conducted following the same protocol in the BSL-II laboratory. 10 ul of purified RNA was used for cDNA generation and library preparation using an Ovation Trio RNA-Seq Library Preparation Kit (NuGEN, CA, USA) according to the manufacturer's instructions. Three samples, including two saline solutions passing through the bronchoscope and one nuclease-free water, were included as the negative controls. Metatranscriptome sequencing was performed on an Illumina HiSeq 2500/4000 platform (Illumina, United Kingdom).

### Data Processing and Analysis {#sec4.4.2}

Raw sequencing reads were quality controlled as previously described ([@bib42]). Briefly, the FASTQ files were subjected to adaptor trimming, low quality reads removal, and short reads removal using Fastp 0.20.0 ([@bib6]). All clean data were mapped to the human genome GRCh38 using HISAT2 v2.1.0 ([@bib22]) with default parameters. Bam files were sorted by Samtools 1.9 ([@bib24]).

Gene counts were summarized using the featureCounts program ([@bib25]) as part of the Subread package release 2.0.0 (<http://subread.sourceforge.net/>). To identify differentially expressed genes (DEGs) between two groups, genes that were present in less than 50% of samples in both groups and genes with average counts per million (CPM) lower than five in both groups were removed. Remained gene counts were then normalized using the quantile method and the voom method. DEGs were determined with the threshold adjusted p value \< 0.05 and absolute logged fold-change (Log2FC) ≥ 2 using the Bioconductor limma package v3.42.2 ([@bib39]). In presenting the individual case of SARS2, the fold change of each gene was calculated as the ratio of normalized gene expression of each SARS2 individual to the mean expression of Healthy.

For the functional enrichment of DEGs, Ingenuity Pathway Analysis (IPA, Ingenuity Systems, Inc.) ([@bib23]) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis ([@bib21]) were applied via IPA December 2019 release (v499329) and the Bioconductor clusterProfiler package v3.14.3 ([@bib50]), respectively. Protein-protein interaction (PPI) networks of upregulated DEGs were built using STRING v11 ([@bib45]) with a confidence score threshold of 0.9 and plotted with Cytoscape v3.7.1 ([@bib41]).

To infer the composition of immune cells in BALF, raw gene counts were normalized as transcripts per million (TPM) and processed using the CIBERSORT algorithm v1.06 ([@bib34]) with the original CIBERSORT gene signature file LM22 and 100 permutations. Twenty-two immune cell subtypes were obtained and further summarized into nine major immune cell types. Samples with p-value \< 0.05, which reflects the statistical significance of the deconvolution results across all cell subsets, were included.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

Fisher's exact test was used for categorical variables, and the Mann-Whitney test was used for continuous variables that do not follow a normal distribution. P values from multiple testing were adjusted (q-value) using the Benjamini-Hochberg false discovery rate (FDR) with a significance level of 0.05 ([@bib1]).

Supplemental Information {#app2}
========================

Document S1. Figures S1--S3 and Table S2 Table S1. Demographic and Clinical Information, Related to Figure 1 and STAR MethodsDemographic and clinical information of all subjects were shown. The criterion for virus infection (Virus) is at least supported by 100 viral reads and should be 10 times higher than the abundance in the negative control by sequencing. Table S3. DEGs in BALF of COVID-19 and CAP Patients Comparing to Healthy Controls, Related to Figure 1DEGs identified by comparing SARS2 to Healthy (Table S3A), Virus-like CAP to Healthy (Table S3B), and Non-viral CAP to Healthy (Table S3C) were presented. An adjusted p value (q-value \< 0.05) and fold change (FC) ratio (\|log2FC\| ≥ 2) were used to determine the DEGs. Table S4. ISGs in SARS-CoV-2 and Other Viral Infections, Related to Figure 3ISGs identified in viral infections were assigned to five previously established functional clusters, including RNA processing (C1 and C2), IFN regulation/antiviral function (C3), metabolic regulation (C4), and inflammation regulation (C5). Document S2. Article plus Supplemental Information
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